Use of High-Resolution Computed Tomography and Positron Emission Tomography/Computed Tomography in the Management of Stage IA Adenocarcinoma

Seminars in Thoracic and Cardiovascular Surgery

Volumn 24, Issue 4, 2012, Pages 267-274

  Miyata, Yoshihiro ^a   Tsutani, Yasuhiro ^a   Okada, Morihito ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Adenocarcinoma; FDG PET CT; HRCT; Lung

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 2;

ARTICLE; CANCER INVASION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL EVALUATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; GLUCOSE METABOLISM; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; LOBECTOMY; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; PLEURA METASTASIS; PROTEIN EXPRESSION; RADIATION DOSE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STRATEGIC PLANNING; SURVIVAL TIME; TREATMENT RESPONSE; UPREGULATION;

ADENOCARCINOMA; DISEASE-FREE SURVIVAL; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MULTIMODAL IMAGING; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84875384765     PISSN: 10430679     EISSN: 15329488     Source Type: Journal    
DOI: 10.1053/j.semtcvs.2012.10.006     Document Type: Article

References (40)

1. Okada M., Koike T., Higashiyama M., et al. Radical sublobar resection for small-sized non-small cell lung cancer: A multicenter study. J Thorac Cardiovasc Surg 2006, 132:769-775.
2. Nakayama H., Yamada K., Saito H., et al. Sublobar resection for patients with peripheral small adenocarcinomas of the lung: Surgical outcome is associated with features on computed tomographic imaging. Ann Thorac Surg 2007, 84:1675-1679.
3. Aberle D.R., Adams A.M., et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011, 365:395-409. National Lung Screening Trial Research Team.
4. Nakata M., Saeki H., Takata I., et al. Focal ground-glass opacity detected by low-dose helical CT. Chest 2002, 121:1464-1467.
5. Jang H.J., Lee K.S., Kwon O.J., et al. Bronchioloalveolar carcinoma: Focal area of ground-glass attenuation at thin-section CT as an early sign. Radiology 1996, 199:485-488.
6. Okada M., Nishio W., Sakamoto T., et al. Correlation between computed tomographic findings, bronchioloalveolar carcinoma component, and biologic behavior of small-sized lung adenocarcinomas. J Thorac Cardiovasc Surg 2004, 127:857-861.
7. Okada M., Nishio W., Sakamoto T., et al. Discrepancy of computed tomographic image between lung and mediastinal windows as a prognostic implication in small lung adenocarcinoma. Ann Thorac Surg 2003, 76:1828-1832.
8. Takamochi K., Nagai K., Yoshida J., et al. Pathologic N0 status in pulmonary adenocarcinoma is predictable by combining serum carcinoembryonic antigen level and computed tomographic findings. J Thorac Cardiovasc Surg 2001, 122:325-330.
9. Travis W.D., Garg K., Franklin W.A., et al. Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. J Clin Oncol 2005, 23:3279-3287.
10. Travis W.D., Colby T.V., Corrin B., et al. Histologic typing of lung and pleural tumours, in World Health Organization International Histological Classification of Tumours 1999, 36. Springer, Berlin. (ed 3).
11. Kuriyama K., Seto M., Kasugai T., et al. Ground-glass opacity on thin-section CT: Value in differentiating subtypes of adenocarcinoma of the lung. AJR Am J Roentgenol 1999, 173:465-469.
12. Pieterman R.M., van Putten J.W., Meuzelaar J.J., et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 2000, 343:254-261.
13. Vansteenkiste J., Fischer B.M., Dooms C., et al. Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: Systematic review. Lancet Oncol 2004, 5:531-540.
14. Juweid M.E., Cheson B.D. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 2006, 354:496-507.
15. Cerfolio R.J., Bryant A.S., Ohja B., et al. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg 2005, 130:151-159.
16. Okada M., Tauchi S., Iwanaga K., et al. Associations among bronchioloalveolar carcinoma components, positron emission tomographic and computed tomographic findings, and malignant behavior in small lung adenocarcinomas. J Thorac Cardiovasc Surg 2007, 133:1448-1454.
17. Tsutani Y., Miyata Y., Misumi K., et al. Difference in prognostic significance of maximum standardized uptake value on [18F]-fluoro-2-deoxyglucose positron emission tomography between adenocarcinoma and squamous cell carcinoma of the lung. Jpn J Clin Oncol 2011, 41:890-896.
18. Nakayama H., Okumura S., Daisaki H., et al. Value of integrated positron emission tomography revised using a phantom study to evaluate malignancy grade of lung adenocarcinoma: A multicenter study. Cancer 2010, 116:3170-3177.
19. Okada M., Nakayama H., Okumura S., et al. Multicenter analysis of high-resolution computed tomography and positron emission tomography/computed tomography findings to choose therapeutic strategies for clinical stage IA lung adenocarcinoma. J Thorac Cardiovasc Surg 2011, 141:1384-1391.
20. Tsutani Y., Miyata Y., Nakayama H., et al. Prognostic significance of using solid versus whole tumor size on high-resolution computed tomography for predicting the pathologic malignant grade of tumors in clinical stage IA lung adenocarcinoma: A multicenter study. J Thorac Cardiovasc Surg 2012, 143:607-612.
21. Fischer B., Lassen U., Mortensen J., et al. Preoperative staging of lung cancer with combined PET-CT. N Engl J Med 2009, 361:32-39.
22. Ginsberg R.J., Rubinstein L.V. Randomized trial of lobectomy versus limited resection for T1N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 1995, 60:615-623.
23. Okada M., Yoshikawa K., Hatta T., et al. Is segmentectomy with lymph node assessment an alternative to lobectomy for non-small cell lung cancer of 2 cm or smaller?. Ann Thorac Surg 2001, 71:956-961.
24. Yoshikawa K., Tsubota N., Kodama K., et al. Prospective study of extended segmentectomy for small lung tumors: The final report. Ann Thorac Surg 2002, 73:1055-1059.
25. Kodama K., Doi O., Higashiyama M., et al. Intentional limited resection for selected patients with T1N0M0 non-small cell lung cancer: A single-institution study. J Thorac Cardiovasc Surg 1997, 114:347-353.
26. Okada M., Tsutani Y., Ikeda T., et al. Radical hybrid video-assisted thoracic segmentectomy: Long-term results of minimally invasive anatomical sublobar resection for treating lung cancer. Interact Cardiovasc Thorac Surg 2012, 14:5-11.
27. Jensik R.J., Faber L.P., Milloy F.J., et al. Segmental resection for lung cancer. A fifteen-year experience. J Thorac Cardiovasc Surg 1973, 66:563-572.
28. Ke Q., Costa M. Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol 2006, 70:1469-1480.
29. Griffiths E.A., Pritchard S.A., Welch I.M., et al. Is the hypoxia-inducible factor pathway important in gastric cancer?. Eur J Cancer 2005, 41:2792-2805.
30. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
31. Mamede M., Higashi T., Kitaichi M., et al. [18F]FDG uptake and PCNA, glut-1, and hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia 2005, 7:369-379.
32. Nguyen X.C., Lee W.W., Chung J.H., et al. FDG uptake, glucose transporter type 1, and Ki-67 expressions in non-small-cell lung cancer: Correlations and prognostic values. Eur J Radiol 2007, 62:214-219.
33. Ito T., Noguchi Y., Satoh S., et al. Expression of facilitative glucose transporter isoforms in lung carcinomas: Its relation to histologic type, differentiation grade, and tumor stage. Mod Pathol 1998, 11:437-443.
34. Minami K., Saito Y., Imamura H., et al. Prognostic significance of p53, Ki-67, VEGF and glut-1 in resected stage I adenocarcinoma of the lung. Lung Cancer 2002, 38:51-57.
35. Boellaard R., Oyen W.J., Hoekstra C.J., et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging 2008, 35:2320-2333.
36. Boellaard R., Krak N.C., Hoekstra O.S., et al. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: A simulation study. J Nucl Med 2004, 45:1519-1527.
37. Westerterp M., Pruim J., Oyen W., et al. Quantification of FDG PET studies using standardised uptake values in multi-center trials: Effects of image reconstruction, resolution and ROI definition parameters. Eur J Nucl Med Mol Imaging 2007, 34:392-404.
38. Mawlawi O., Podoloff D.A., Kohlmyer S., et al. Performance characteristics of a newly developed PET/CT scanner using NEMA standards in 2D and 3D modes. J Nucl Med 2004, 45:1734-1742.
39. Suzuki K., Koike T., Asakawa T., et al. A prospective radiological study of thin-section computed tomography to predict pathological noninvasiveness in peripheral clinical IA lung cancer. J Thorac Oncol 2011, 6:751-756. (Japan Clinical Oncology Group).
40. Nakamura K., Saji H., Nakajima R., et al. A phase III randomized trial of lobectomy versus limited resection for small-sized peripheral non-small cell lung cancer (JCOG0802/WJOG4607L). Jpn J Clin Oncol 2010, 40:271-274.